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Background: The skills of patients on oral anticoagulants are critical for achieving good outcomes with this
treatment. Self-management, or the capacity of patients to control their INR level and adjust their treatment, is an
effective strategy of treatment. Capacity of patients to self manage is determined by a range of factors. The
identification of these factors would improve the design of self management programmes and in turn increase the
number of patients able to self-manage. The objective of our study is to identify those factors that determine the
ability of patients on oral anticoagulant therapy to achieve self-management of their treatment.
Design: This will be a three year quasi- experimental prospective study with a control group. 333 patients on
anticoagulant therapy from five health centres of the Basque Health Service are to be followed up for a period of
six months each after the intervention, to assess their ability to self-test and self-manage. The intervention will
consist of a patient training programme involving the provision of information and practical training concerning
their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust
their anticoagulant dose.
Discussion: The ease-of-use of this technique lead us to believe that self-management is feasible and will represent
an innovative advance that should have a substantial impact on the quality of life of this patients and their families
as well as on the health care provision systems.
Trial registration: Osakidetza Protocol Record ISCIII-11/02285, Oral anticoagulation and self-management,
ClinicalTrials.gov Identifier: NCT01878539
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Oral anticoagulants (OACs) are increasingly widely used
for the treatment of cardiovascular diseases, such as
atrial fibrillation (currently its primary indication), valvular
heart disease and venous thromboembolism [1]. Indeed, it
in a relatively short period of time they have become the
treatment of choice for the aforementioned conditions
and are currently used in 1.7-2% of the population in
Spain, reaching 7-8% in people aged 65 and [2] over.* Correspondence: eduardo.tamayoaguirre@osakidetza.net
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distribution, and reproduction in any mediumOACs are effective in preventing thromboembolic events,
but they have a major adverse effect, namely an increased
risk of bleeding [1].
While for OACs to be safe and effective international
normalized ratio (INR) values should be maintained within
narrow margins, measurements outside the normal range
for their condition are common in people on OAC therapy.
Indeed, internal assessments in centres in our region have
estimated that 35-40% of INR measurements (around
19,000) are out of the normal range. Deviation from
the therapeutic range has been associated with new
cardiovascular events such as the development ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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levels respectively [3].
Numerous factors have an impact on INR levels. Keeping
these levels under control and stable is difficult and
requires collaboration, learning and responsibility on the
part of all those involved: general practitioners and nursing
staff as well as patients themselves.
The progressive increase in the number of people on
OACs has led to a corresponding increase in the resources
dedicated to monitoring this treatment. Indeed, some
hospital haematology services have been overwhelmed
by situation, and in response to this several health regions
in Spain have decided to transfer the follow-up and
management of these patients to primary care. In primary
care centres, the role has been taken on by general practi-
tioners and primary care nursing staff who test INR levels
and adjust doses as necessary (referring patients to the
Haematology unit in just 6% of cases).
In this context, an increase in the number of patients able
to self-monitor would have an impact at the organisational
and financial level within the health system itself [4], both
for hospital haematology services and primary care, given
that management has been transferred to this level of care
in many cases.
Moreover, there is an international consensus that
self-monitoring [2] is a key element for improving the
management of patients on OAC therapy. Internationally,
several pilot studies [5] have been set up exploring patient
self-testing (ability to use a coagulometer for measuring
INR values) and self-management (ability to adjust doses
according to the INR changes). These interventions,
involving active selection of patients and subsequently
providing them with training, have demonstrated that
around 50% of patients are able to adequately monitor
and manage their treatment [6,7]. Some interventions
carried out in Spain, specifically in Andalucía, Cataluña,
Castilla y León and Aragón (EviBased Nurs 2005: 8: 87
doi: 10.1136/ebn.8.3.87) [4,7] have produced results
confirming these findings. Notably, in some studies it has
been found that patients who self-manage have lower
rates of cardiovascular events and have significantly lower
rates of thromboembolic and bleeding complications [5,8].
Many patients are able to monitor and even control
factors that affect the therapeutic ranges and, in such cases,
it is appropriate for them to take partial responsibility for
managing their treatment. For this, however, patients must
be trained how to use portable coagulometers and hence
monitor their INR levels themselves, supported by health
professionals [8-11].
Training programmes for self-management are effective
in terms of enabling patients to acquire the necessary skills,
though the level of success seems to depend on various
patient-related factors. Given the proven benefits of self-
management, it would be useful to properly characterisethese factors and use this information to successfully
increase the percentage of patients on OACs able to
self-manage their own treatment.
Design
This will be a quasi-experimental prospective study with a
control group. Patients on anticoagulant therapy from five
health centres of the Basque Health Service are to be
followed up for a period of six months after the interven-
tion, to assess their ability to self-monitor and self-manage.
Hypothesis
An intervention program targeting patients and caregivers
based on education about their condition and training in
the use of portable coagulometer to self-monitor and
training on the treatment adjustment to self manage,
can be effective to enable patients in OACs to self manage
as well as to identify determinant factors associated with
the success and failure of the program.
Primary objectives
1. To assess the ability of patients/caregivers to self manage
OAC treatment (to test INR levels with a portable
coagulometer and capillary whole blood from a finger prick
and to adjuste OAC doses accordingly) 2. To evaluate the
impact of a range of factors on the capacity of patients on
OACs to self-monitor and self-manage.
Secondary objectives
1. To compare the incidence of adverse effects in patients
in the control and intervention groups 2. To compare the
rate of in-range INR (i.e., levels within the therapeutic
range) in patients in the control and intervention groups
3. To assess the impact on the quality of life of the
self-management programme 4.To describe the attitudes
and opinions of health professionals and patients with
respect to the self-management programme.
Methods
A pilot study has been conducted, over 33 patients, to
identify potential determinant factors to be studied, to
assess the methodology of the intervention and any
technical problems related to the use coagulometers.
The pilot study has already finished and has no lead to
relevant changes in the main study protocol. Their results
are being processed in order to be published.
Subsequently, a multi-centre, interventional study will be
performed with a control group with an overall duration of
three years. The target population for this study is patients
on OAC therapy for any reason, aged above 16 years
and under the care of participating health centres in an
urban area. These health centres cover a population of
over 200,000 and currently 1.7% of this population is on
anticoagulants (approximately 3400 individuals).
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not live in the area on a regular basis, have any serious
diseases (including kidney or liver failure, or any terminal
conditions), have been less than six months on OAC
therapy or decline to participate. From the pool of
elegible patients, the sample will be randomly selected,
with a number of reserve subjects. These selected patients
will be provided with information about the objectives
and methodology of the study and asked to participate.
Among these, some will be willing to be part of the inter-
vention group and will be included in it, and some will
not be interested in receive the intervention, and these
will be considered for the comparison control group,
both groups of patients should provide consent for their
participation in the intervention and for their clinical
records to be reviewed by the research team in the case
of control group. This non random patient assignation
method, is the reason of this study being defined as
quasi-experimental and not a clinical trial.
The proposed sample size is 333 individuals. In order
to derivate predictive models based on logistic regression
models it is necessary to include at least ten final events
for each of the independent variable included in the
model (Laupacis A et al.; Vittinghoff E et al.). It is
our intent to propose a model including less than ten
independent variables, so, considering “successful self
management” as our final event, 100 successful subjects
will be necessary to guarantee a proper convergence of the
model. Published studies [7] show that the success rate in
this kind of self management programs stands around
50%, so we considered that in order to compare both
groups, it would be necessary to have 100 successful patient
and 100 non successful. Another study of Fitzmaurice [11]
shows that a 40% of participants did not complete this
type of program, so 333 subjects will be necessary in order
to have the required sample size.
The intervention will consist of two sessions of participa-
tive training leaded by trained nurses. First, an educational
workshop will be run with the goal of improving patient
understanding of their condition and OAC treatment.
Then, a second workshop will be run focused on training
patients how to use a coagulometer and how to adjust their
OAC doses, that is, the skills necessary to self-monitor and
self-manage. In this second session, a coagulometer and
a record sheet will be given to each patient as well as a
telephone number to seek advice for any problems or
questions that may arise during the follow-up period.
The follow up period will last 6 months for each subject.
Several intervention groups will be constituted and the
intervention will be implemented consequently for each
group, giving the project a total period of three years for
its execution.
During this follow up period, patient will be provided
free access to sanitary advice and a monthly follow-up visitwill be scheduled with their assigned health professionals.
Any reported incidents and weekly INR records kept by
the patients will be registered, as will be details arised
during the follow up visits.
Data will be collected on the use of the coagulometer,
the INR measurements, the visits and any advice or support
sought during the self-monitoring period. Other potentially
relevant variables will also be analysed including age;
use of multiple medications; willingness to take on self-
management of their condition and treatment; social and
cultural status; and presence of serious illnesses, conditions
associated with tremor, multiple diseases, or blindness;
as well as patient knowledge of their own disease and
the reason for anticoagulation treatment. Particular atten-
tion will be paid to recording any thrombotic or bleeding
episodes.
The main final event, “successful self management”
will be defined as patients finishing the follow up period
with less than 30% of INR determinations out of range
and no thrombotic or bleeding episodes.
For self-monitoring, latest generation portable coagu-
lometers will be used; these devices have improved com-
pared to previous models and can be linked to a computer
to download the data for processing.
Patients in the control group will receive regular care
from their general practitioners. Data to calculate the
rate of in-range INR (levels within the therapeutic range),
and the incidence of adverse effects will be retrieved from
the electronic clinical record for the six months follow-up
period.
The attitude of health professionals, both doctors and
nurses, with regards to whether they would advise self-
monitoring and management in patients on OAC therapy
will be analysed, using a questionnaire prior to the start of
the study.
The project has been approved by the ethical committee
“Comité Ético de Investigación Clínica del Área Sanitaria
de Gipuzkoa” on November, the 23th 2011.
The project is funded by Carlos III Health Institute
(a grant from the Spanish Health Research Fund, FIS
(PI11/02285) and “Centro de Excelencia en Investigación
en Cronicidad, Kronikgune” (Kronik 11/053).Discussion
Potential impact of the results
In Spain, 1.7-2% of the general population and 7-8% of
those above 65 years of age [1] are on OACs. Given that
the mean age and life expectancy of the population is
progressively increasing and that chronic disorders that
require treatment with OACs are associated in most cases
with age, the number of patients taking OACs in the near
future can be expected to rise and to do so in proportion
to the size of the over-70-year-old population.
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has hardly begun to be developed in our country [6],
although it is estimated that about 50% of people on
OACs are candidates for this approach. In the Basque
Country (Spain), this figure corresponds to around 37,000
people (1.7% of the general population of around 2,178,000
people; Basque Institute of Statistics, March 2012).
At the same time, the latest information and communi-
cation technologies, the introduction in our health system
of “Expert Patient”-type programmes and the ease-of-use
of this technique lead us to believe that self-management
is feasible and will represent an innovative advance that
should have a substantial impact on the quality of life of
this type of patients and their families as well as on the
health care provision systems.
We are aware that other potential therapeutic alternatives
are appearing, and new generation devices may be even
easier to use, but they are still under research and add-
itional data are necessary to assess their future introduction
in primary care practice.
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